创新药企鞍石生物冲刺科创板采用第五套上市标准

Core Viewpoint - An innovative biopharmaceutical company, Beijing Anshi Biotechnology Co., Ltd. (Anshi Bio), has received acceptance for its IPO application on the Sci-Tech Innovation Board, aiming to raise 2.45 billion yuan for its operations and new drug development [1][3]. Group 1: Company Overview - Anshi Bio is focused on developing innovative anti-tumor drugs to address significant unmet clinical needs, with its main product, Wanbi Rui (Bertinib), already commercialized [1]. - The company has a pipeline that includes Wanbi Rui, which has been approved for sale, and other drugs like Andai Aitini, currently under review, and ANS01 and ANS03, which are in clinical trials [1]. Group 2: Financial Performance - Anshi Bio reported no revenue prior to the approval of Bertinib, indicating a history of operating losses [2]. - Financial data shows revenues of approximately 0, 12.96 million yuan, 71.66 million yuan, and 64.04 million yuan for the years 2022 to 2025 (Q1), with corresponding net losses of about -163.68 million yuan, -282.72 million yuan, -478.71 million yuan, and -91.65 million yuan [2]. Group 3: IPO and Fund Utilization - The company plans to use the 2.45 billion yuan raised from the IPO for new drug research and development (1.95 billion yuan) and to supplement working capital (500 million yuan) [4]. - The acceptance of Anshi Bio's IPO application under the fifth set of listing standards indicates ongoing support from the capital market for innovative drug companies [3]. Group 4: Goodwill and Risks - Anshi Bio has recorded significant goodwill of 927 million yuan following the acquisition of Beijing Purun Ao, which is responsible for the development of Bertinib [4]. - The company has acknowledged potential risks related to goodwill impairment due to changes in the operational performance of Beijing Purun Ao or adverse external factors [4].